Get the Stockscreener App
9.29
0.43%
0.04
After Hours:
9.24
-0.05
-0.54%
Kura Oncology Inc stock is traded at $9.29, with a volume of 816.34K.
It is up +0.43% in the last 24 hours and up +7.90% over the past month.
Kura Oncology Inc is a biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for the treatment of cancer. The company develops small-molecule medicines designed to target cancer signaling pathways in oncology and hematology. Its pipeline includes menin inhibitor ziftomenib for the treatment of acute myeloid leukemia and other hematologic malignancies, as well as additional product candidates such as KO-7246 and darolifarnib being evaluated for solid tumors and other diseases.
See More
Previous Close:
$9.25
Open:
$9.34
24h Volume:
816.34K
Relative Volume:
0.57
Market Cap:
$824.61M
Revenue:
$67.48M
Net Income/Loss:
$-278.67M
P/E Ratio:
-2.9238
EPS:
-3.1774
Net Cash Flow:
$-70.70M
1W Performance:
+5.21%
1M Performance:
+7.90%
6M Performance:
-6.54%
1Y Performance:
+38.24%
1-Day Range:
$9.035
$9.415
1-Week Range:
$8.53
$9.42
52-Week Range:
$5.45
$12.49
Kura Oncology Inc Stock (KURA) Company Profile
Name
Kura Oncology Inc
Sector
Industry
Phone
(858) 500-8800
Address
4930 DIRECTORS PLACE, SUITE 500, SAN DIEGO, CA
Compare KURA vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
KURA
Kura Oncology Inc
|
9.29 | 821.06M | 67.48M | -278.67M | -70.70M | -3.1774 |
VRTX
Vertex Pharmaceuticals Inc
|
424.36 | 109.34B | 12.32B | 4.34B | 3.19B | 16.86 |
REGN
Regeneron Pharmaceuticals Inc
|
702.27 | 74.35B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
794.70 | 50.44B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
301.11 | 39.78B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
297.49 | 33.02B | 5.36B | 287.73M | 924.18M | 2.5229 |
Kura Oncology Inc Stock (KURA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-14-26 | Initiated | Lake Street | Buy |
| Sep-04-25 | Initiated | Guggenheim | Neutral |
| Feb-06-25 | Downgrade | BTIG Research | Buy → Neutral |
| Oct-24-24 | Initiated | UBS | Buy |
| Oct-14-24 | Downgrade | Stifel | Buy → Hold |
| Dec-22-23 | Initiated | Mizuho | Buy |
| Aug-11-23 | Initiated | BofA Securities | Buy |
| Jul-27-23 | Initiated | Scotiabank | Sector Perform |
| May-17-23 | Initiated | BTIG Research | Buy |
| Jan-31-23 | Initiated | Stifel | Buy |
| Jul-12-22 | Initiated | Cantor Fitzgerald | Overweight |
| Feb-15-22 | Initiated | Jefferies | Buy |
| May-05-21 | Resumed | Credit Suisse | Outperform |
| Apr-26-21 | Resumed | Credit Suisse | Outperform |
| Dec-07-20 | Reiterated | H.C. Wainwright | Buy |
| Dec-03-20 | Initiated | Stifel | Buy |
| Nov-05-20 | Downgrade | Piper Sandler | Overweight → Neutral |
| Jul-07-20 | Initiated | Credit Suisse | Outperform |
| May-05-20 | Initiated | Barclays | Overweight |
| Jul-18-19 | Initiated | Deutsche Bank | Buy |
| Nov-09-18 | Initiated | Piper Jaffray | Overweight |
| Aug-01-18 | Initiated | H.C. Wainwright | Buy |
| Oct-13-16 | Resumed | Leerink Partners | Outperform |
| Jan-22-16 | Initiated | JMP Securities | Mkt Outperform |
| Dec-30-15 | Initiated | Oppenheimer | Outperform |
| Dec-16-15 | Initiated | Citigroup | Buy |
View All
Kura Oncology Inc Stock (KURA) Latest News
Kura Oncology schedules May 12 webcast for Q1 2026 results - Stock Titan
Kura Oncology to Report First Quarter 2026 Financial Results - Yahoo Finance
How The Kura Oncology (KURA) Story Is Evolving After Komzifti Launch And Q4 Reassessment - Yahoo Finance
Five new Kura hires get stock options for 133,750 shares - Stock Titan
Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - marketscreener.com
KURA Stock Price, Quote & Chart | KURA ONCOLOGY INC (NASDAQ:KURA) - ChartMill
Vanguard reports 5.01% stake in Kura Oncology (NASDAQ: KURA) - Stock Titan
Kura Oncology (KURA) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release - Yahoo Finance
Kura Oncology (KURA) Projected to Post Quarterly Earnings on Thursday - MarketBeat
Moody Aldrich Partners LLC Buys New Position in Kura Oncology, Inc. $KURA - MarketBeat
Kyowa Kirin and Kura Oncology Initiate Japanese Phase 2 Registration-Directed Trial of Ziftomenib in R/R NPM1-m AML - marketscreener.com
Kyowa Kirin Co., Ltd. And Kura Oncology, Inc. Advance Ziftomenib With Japan Phase 2 Trial In NPM1 Mutated AML - BioPharma APAC
Kura rises after early-stage trial data for kidney cancer therapy - MSN
Kura Oncology shares jump on encouraging kidney cancer trial results - MSN
KURA Financials: Income Statement, Balance Sheet & Cash Flow | Kura Oncology Inc - Stock Titan
Kura Oncology, Inc. (NASDAQ:KURA) Q4 2025 earnings call transcript - MSN
Kura Oncology, Inc. (KURA) Discusses Updated Data on Darlifarnib and Cabozantinib Combination in Advanced Renal Cell CarcinomaSlideshow (NASDAQ:KURA) 2026-04-21 - Seeking Alpha
Barclays Sticks to Their Buy Rating for Kura Oncology (KURA) - The Globe and Mail
Kura Oncology: Poised For A Lift With Combinations (NASDAQ:KURA) - Seeking Alpha
Is Kura Oncology (KURA) stock expanding in volatility (+1.45%) 2026-04-20Community Sell Signals - Cổng thông tin điện tử tỉnh Tây Ninh
KURA Stock Rallies 8% on Strong Preliminary Renal Cancer Study Data - TradingView
H.C. Wainwright Maintains Kura Oncology(KURA.US) With Buy Rating, Maintains Target Price $40 - Moomoo
Kura Oncology (KURA) Moves 8.3% Higher: Will This Strength Last? - Yahoo Finance
Kura Oncology, Inc. (NASDAQ:KURA) Given Average Recommendation of "Moderate Buy" by Brokerages - MarketBeat
How The Kura Oncology (KURA) Narrative Is Shifting With Komzifti Launch And New Analyst Targets - Yahoo Finance
Kura Oncology Advances Kidney Cancer Program With Solid Early-Stage Results - Sahm
KURA: Promising Results from Kura Oncology's Trial on ccRCC Trea - GuruFocus
LifeSci Capital Maintains Kura Oncology(KURA.US) With Buy Rating, Maintains Target Price $28 - Moomoo
Kura Oncology (NASDAQ:KURA) Stock Price Up 9.7%Time to Buy? - MarketBeat
Kura Oncology (KURA) Shows Promising Phase 1 Trial Results for K - GuruFocus
Kura Oncology shares jump on positive kidney cancer trial data By Investing.com - Investing.com Canada
Kura Oncology Inc at TD Cowen Healthcare Conference Transcript - GuruFocus
Kura Oncology Reports Darlifarnib Plus Cabozantinib Demonstrates Robust Activity in Patients With Clear Cell Renal Cell Carcinoma Previously Treated With Cabozantinib - The Manila Times
Kura Oncology Announces Promising Preliminary Data on Darlifarnib in Combination with Cabozantinib for ccRCC Patients Previously Treated with Cabozantinib - Quiver Quantitative
Kura Oncology Reports Darlifarnib Plus Cabozantinib Demonstrates Robust Activity in Patients ... - Enidnews.com
Kura Oncology Reports Darlifarnib Plus Cabozantinib - GlobeNewswire
Kura Oncology, Inc. (KURA) Stock Analysis: A 247% Upside Potential Beckons Investors - DirectorsTalk Interviews
Kura Oncology shares jump on positive kidney cancer trial data - Investing.com
Kura Oncology (NASDAQ:KURA) Raised to Strong-Buy at Lake Street Capital - MarketBeat
Lake Street initiates coverage of Kura Oncology (KURA) with buy recommendation - MSN
Kura Oncology Inc Stock (KURA) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.14%
0.48%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):